Larnamine - Instructions For Use, Price, Analogues, Reviews

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Larnamine

Larnamine: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacological properties
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Application during pregnancy and lactation
10. 10. Use in childhood
11. 11. In case of impaired renal function
12. 12. For violations of liver function
13. 13. Drug interactions
14. 14. Analogs
15. 15. Terms and conditions of storage
16. 16. Terms of dispensing from pharmacies
17. 17. Reviews
18. 18. Price in pharmacies

Latin name: Larnamin

ATX code: A05BA

Active ingredient: ornithine (Ornithine)

Manufacturer: PJSC "Farmak" (Ukraine)

Description and photo update: 2019-24-07

Larnamine is a hypoazotemic drug used for liver diseases.

Release form and composition

• granules for oral solution: a mixture of orange and white granules of various sizes (5 g in a sachet, in a cardboard box 10 or 30 sachets);
• concentrate for preparation of solution for infusion: clear liquid from colorless to pale yellow (in 10 ml ampoules: in a carton of 5 or 10 ampoules; in a blister 5 ampoules, in a carton of 1 or 2 blisters).

The drug is accompanied by instructions for the use of Larnamin.

5 g of granules for oral solution (1 sachet) contains:

• active substance: L-ornithine-L-aspartate - 3 g (in terms of 100% substance);
• additional components: sodium cyclamate, sodium saccharin, povidone, anhydrous citric acid, lemon flavoring, orange flavoring, maltitol (E 965), sunset yellow FCF (E 110).

1 ml of concentrate for preparation of solution for infusion contains:

• active substance: L-ornithine-L-aspartate - 0.5 g (in terms of 100% substance);
• additional component: water for injection.

Pharmacological properties

Pharmacodynamics

In vivo, the effect of the active ingredient is due to amino acids (aspartate and ornithine) and is carried out using two key methods of ammonia detoxification, such as the formation of urea and the synthesis of glutamine. Urea production occurs in peri-portal hepatocytes, where ornithine plays the role of an activator of two enzymes - ornithine carbamoyltransferase and carbamoylphosphate synthetase, and is also a substrate for urea synthesis.

The process of glutamine production takes place in the paravenous hepatocytes. Against the background of pathological conditions, aspartate and dicarboxylate, including the metabolic products of ornithine, are absorbed into cells, where they are used to bind ammonia in the form of glutamine.

Glutamate refers to amino acids that bind ammonia under both physiological and pathological conditions. The synthesized amino acid glutamine is not only a non-toxic form for the elimination of ammonia, but also activates an important ornithine cycle (the formation of urea from ammonia) - the intracellular metabolism of glutamine. Under physiological conditions, aspartate and ornithine do not restrict urea production.

According to experimental animal studies, it was found that the ability of L-ornithine-L-aspartate to reduce ammonia is associated with the accelerated production of glutamine.

Larnamine promotes the production of insulin and growth hormone, and also normalizes protein metabolism in diseases that require parenteral nutrition.

Pharmacokinetics

The half-life of active metabolites of the active substance - ornithine and aspartate - is 0.3–0.4 hours. A small part of aspartate is excreted unchanged in the urine.

Indications for use

Larnamine is recommended for use for the treatment of diseases and complications caused by impaired liver detoxification function (including liver cirrhosis) with signs of latent or severe hepatic encephalopathy, especially (for concentrate) with impaired consciousness (precoma, coma).

Also Larnamine in the form of a concentrate is used as a corrective additive to parenteral nutrition products in the presence of protein deficiency.

Contraindications

Absolute:

• severe renal impairment (chronic / acute renal failure) with a serum creatinine content of more than 3 mg / 100 ml;
• age up to 18 years;
• breast-feeding;
• hypersensitivity to any component of the drug.

During pregnancy, use of Larnamine should be avoided. It can be prescribed only for health reasons, under the strict supervision of the attending physician, taking into account the ratio of the expected benefits for the woman and the possible threat to the health of the fetus.

Larnamine, instructions for use: method and dosage

Granules for oral solution

Granules at a dose of 5-10 g (contents of 1-2 sachets) are recommended to be diluted in a large amount of liquid, for example, in 200 ml (1 glass) of water or juice, and taken up to 3 times a day during or after meals.

Concentrate for solution for infusion

The solution for infusion should be infused intravenously (IV) by drop. As a rule, the daily dose is 40 ml of concentrate (4 ampoules). In case of precoma or coma, it is increased to 80 ml (8 ampoules) within 24 hours, taking into account the severity of the condition.

Before intravenous administration, the contents of ampoules (no more than 6 pcs.) Are recommended to be dissolved in 500 ml of a solution for infusion - 0.9% sodium chloride solution, 5% dextrose (glucose) solution or Ringer's solution. The maximum rate of intravenous infusion of the prepared infusion solution should not exceed 5 g / h, which is equivalent to the amount of concentrate in 1 ampoule.

The course of therapy for both dosage forms of Larnamine is established by the attending physician individually, depending on the pathology and severity of the condition.

Side effects

• digestive tract: nausea, vomiting (extremely rare for concentrate); additionally for granules - flatulence, stomach pain, diarrhea;
• musculoskeletal system (for granules): joint pain.

These disorders are usually short-term and do not require discontinuation of drug therapy. In most cases, side effects disappear when the dose or rate of IV administration is reduced.

Sometimes, against the background of using the solution for infusion, allergic reactions may occur.

Overdose

Currently, signs of intoxication associated with an overdose of Larnamine have not been recorded. When this condition occurs, there may be an aggravation of the severity of undesirable effects. If you suspect an overdose, you should stop using the drug and carry out symptomatic treatment.

special instructions

The prepared infusion solution should not be injected into the artery.

Due to the fact that studies on the compatibility of Larnamine have not been conducted, the concentrate for the preparation of a solution for infusion should not be mixed with other means, with the exception of the infusion solutions specified in the section "Method of administration and dosage".

When using high doses of a hypoazotemic agent, it is necessary to monitor the urea content in the blood plasma, as well as in the urine.

Influence on the ability to drive vehicles and complex mechanisms.

Against the background of treatment with Laraminamine, the ability to drive a car or other complex moving mechanisms may deteriorate, as a result of which it is recommended to refrain from such activities during the period of using the drug.

Application during pregnancy and lactation

There are no data on the use of Larnamine in pregnant women. The study of the toxic effects of Larnamine on reproductive function in animal studies has not been carried out.

During pregnancy, treatment with Laraminine should be avoided. The use of the drug is possible only for health reasons, under the strict supervision of the attending physician, taking into account the ratio of the expected benefits for the woman and the possible threat to the health of the fetus.

Since there is no data on the excretion of Larnamine in breast milk, its use during lactation is contraindicated. If the prescription of the drug is justified, breastfeeding must be stopped for the period of therapy.

Pediatric use

In pediatric practice, Larnamine is not used, since the experience of its use in children and adolescents is limited.

With impaired renal function

In the presence of severe functional impairment of the kidneys (with a serum creatinine level of more than 3 mg / 100 ml), drug therapy is contraindicated.

For violations of liver function

With the existing violations of the liver in a severe degree, it is necessary to carefully monitor the patient's condition and adjust the rate of administration of the infusion solution in order to prevent the occurrence of nausea and vomiting.

Drug interactions

Until now, the interaction of Larnamine with other drugs has not been established.

Analogs

Ornithine, Hepa-Merz, Ornilatex, Ornithine Canon are analogues of Larnamine.

Terms and conditions of storage

Store out of the reach of children at a temperature not exceeding 25 ° C.

Shelf life is 2 years.

Terms of dispensing from pharmacies

Concentrate for solution for infusion is available with a prescription, granules for oral solution - without a prescription.

Reviews about Larnamin

Currently, on medical sites, there are no reviews left by patients or specialists about Larnamine, according to which one could objectively assess its advantages and disadvantages.

Price for Larnamine in pharmacies

There is no reliable information on the price of Larnamine, since the drug is currently not available in the pharmacy network. The cost of an analogue of the drug, Ornithine Canon (granules for preparing a solution for oral administration, 5 g in a sachet), averages 1040 rubles. per package containing 30 sachets.

Maria Kulkes Medical journalist About the author

Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!